After CARDAMYST’s December 12th, 2025 approval, investors have shifted focus to payer coverage and whether prescriptions can ramp fast enough to narrow losses.
After CARDAMYST’s December 12th, 2025 approval, investors have shifted focus to payer coverage and whether prescriptions can ramp fast enough to narrow losses.This article was originally published by Finimize.
Read Full Story on Source Site →
